{"id":64714,"date":"2026-05-08T14:26:33","date_gmt":"2026-05-08T06:26:33","guid":{"rendered":"https:\/\/flcube.com\/?p=64714"},"modified":"2026-05-08T14:26:34","modified_gmt":"2026-05-08T06:26:34","slug":"wuhan-yzy-biopharmas-bispecific-antibody-m701-receives-nmpa-acceptance-for-review-in-malignant-ascites-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64714","title":{"rendered":"Wuhan YZY Biopharma&#8217;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment"},"content":{"rendered":"\n<p><strong>Wuhan YZY Biopharma Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2496:HKG\">HKG: 2496<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review its <strong>New Drug Application (NDA)<\/strong> for <strong>M701<\/strong>, a <strong>bispecific antibody (BsAb)<\/strong> targeting <strong>malignant ascites caused by advanced epithelial malignancies<\/strong>. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-overview\">Regulatory Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>M701 (bispecific antibody)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>EpCAM (tumor cell target) + CD3 (T-cell activation target)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Malignant ascites from advanced epithelial malignancies<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Intraperitoneal infusion<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NDA accepted for review by NMPA<\/td><\/tr><tr><td><strong>Commercial Partner<\/strong><\/td><td>Chia Tai Tianqing (CTTQ) \u2013 exclusive license for mainland China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-therapeutic-innovation\">Mechanism of Action &amp; Therapeutic Innovation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-targeting-strategy\">Dual-Targeting Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EpCAM Binding<\/strong>: Targets epithelial cell adhesion molecule expressed on tumor cells from epithelial malignancies<\/li>\n\n\n\n<li><strong>CD3 Engagement<\/strong>: Activates T cells through CD3 receptor engagement, triggering cytotoxic response<\/li>\n\n\n\n<li><strong>Tumor-Immune Bridging<\/strong>: Simultaneous binding creates immunological synapse between tumor cells and T cells<\/li>\n\n\n\n<li><strong>Localized Therapy<\/strong>: Intraperitoneal delivery concentrates immune activation within abdominal cavity where malignant ascites accumulates<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-advantages\">Clinical Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Targeting<\/strong>: Selective activation of T cells only in proximity to EpCAM-positive tumor cells<\/li>\n\n\n\n<li><strong>Reduced Systemic Toxicity<\/strong>: Localized administration minimizes systemic immune-related adverse events<\/li>\n\n\n\n<li><strong>Addressing Unmet Need<\/strong>: First-in-class approach for malignant ascites, a condition with limited therapeutic options<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-partnership-framework\">Commercial Partnership Framework<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chia-tai-tianqing-cttq-agreement\">Chia Tai Tianqing (CTTQ) Agreement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>License Type<\/strong>: Exclusive, sublicensable rights for mainland China<\/li>\n\n\n\n<li><strong>Scope<\/strong>: Development, registration, manufacturing, and commercialization<\/li>\n\n\n\n<li><strong>Partnership Rationale<\/strong>: Leverages CTTQ&#8217;s established oncology commercial infrastructure and regulatory expertise<\/li>\n\n\n\n<li><strong>Revenue Structure<\/strong>: Upfront payment, development milestones, and tiered royalties on net sales<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-access-strategy\">Market Access Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Positioning<\/strong>: Premium pricing justified by novel mechanism and unmet medical need<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong>: Target inclusion in <strong>National Reimbursement Drug List (NRDL)<\/strong> following approval<\/li>\n\n\n\n<li><strong>Distribution Network<\/strong>: CTTQ&#8217;s extensive hospital coverage ensures rapid market penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-malignant-ascites-burden\">Malignant Ascites Burden<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Estimated <strong>150,000\u2013200,000 patients annually<\/strong> in China with malignant ascites from epithelial cancers<\/li>\n\n\n\n<li><strong>Current Standard of Care<\/strong>: Primarily <strong>paracentesis<\/strong> (fluid drainage) with no disease-modifying therapies approved<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: High recurrence rates and poor quality of life with existing palliative approaches<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: No approved bispecific antibodies for malignant ascites globally<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Localized delivery approach distinct from systemic immunotherapies<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: Strong patent protection covering composition, method of use, and manufacturing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-and-strategic-implications\">Investment and Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Review Period<\/strong>: Standard 200-day review timeline; potential priority review consideration<\/li>\n\n\n\n<li><strong>Approval Expectation<\/strong>: Decision anticipated Q1 2027<\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: Rapid market entry planned through CTTQ partnership infrastructure<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Sales Estimate<\/strong>: Analysts project <strong>\u00a5800 million\u20131.2 billion<\/strong> ($110\u2013170 million) annual revenue at peak adoption<\/li>\n\n\n\n<li><strong>Royalty Revenue<\/strong>: YZY Bio expected to receive <strong>15\u201325%<\/strong> royalty rate on net sales<\/li>\n\n\n\n<li><strong>Valuation Impact<\/strong>: NDA acceptance represents de-risking milestone; potential 30\u201350% stock appreciation upon approval<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-significance\">Pipeline Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Flagship Asset<\/strong>: M701 represents YZY Bio&#8217;s most advanced clinical candidate<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success validates company&#8217;s bispecific antibody platform for localized delivery applications<\/li>\n\n\n\n<li><strong>Future Indications<\/strong>: Potential expansion to other peritoneal malignancies and localized tumor microenvironments<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review timelines, commercial projections, and partnership outcomes for M701. Actual results may vary due to regulatory decisions, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050701259_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026050701259_c.\"><\/object><a id=\"wp-block-file--media-ba66f3da-b31e-46dc-9d88-a5b048e69ee7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050701259_c.pdf\">2026050701259_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050701259_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ba66f3da-b31e-46dc-9d88-a5b048e69ee7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[661,928,38,137],"class_list":["post-64714","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-2496","tag-market-approval-filings","tag-yzy-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Wuhan YZY Biopharma&#039;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64714\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wuhan YZY Biopharma&#039;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment\" \/>\n<meta property=\"og:description\" content=\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64714\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:26:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:26:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Wuhan YZY Biopharma&#8217;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment\",\"datePublished\":\"2026-05-08T06:26:33+00:00\",\"dateModified\":\"2026-05-08T06:26:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714\"},\"wordCount\":536,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 2496\",\"Market approval filings\",\"YZY Biopharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64714#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64714\",\"name\":\"Wuhan YZY Biopharma's Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T06:26:33+00:00\",\"dateModified\":\"2026-05-08T06:26:34+00:00\",\"description\":\"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64714\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64714#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wuhan YZY Biopharma&#8217;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wuhan YZY Biopharma's Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64714","og_locale":"en_US","og_type":"article","og_title":"Wuhan YZY Biopharma's Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment","og_description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.","og_url":"https:\/\/flcube.com\/?p=64714","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:26:33+00:00","article_modified_time":"2026-05-08T06:26:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64714#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64714"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Wuhan YZY Biopharma&#8217;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment","datePublished":"2026-05-08T06:26:33+00:00","dateModified":"2026-05-08T06:26:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64714"},"wordCount":536,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chia Tai Tianqing Pharmaceutical","HKG: 2496","Market approval filings","YZY Biopharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64714#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64714","url":"https:\/\/flcube.com\/?p=64714","name":"Wuhan YZY Biopharma's Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T06:26:33+00:00","dateModified":"2026-05-08T06:26:34+00:00","description":"Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for M701, a bispecific antibody (BsAb) targeting malignant ascites caused by advanced epithelial malignancies. The novel therapy employs dual-target binding to bridge tumor cells and immune T cells, activating localized immune response within the abdominal cavity through intraperitoneal infusion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64714#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64714"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64714#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Wuhan YZY Biopharma&#8217;s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64714"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64714\/revisions"}],"predecessor-version":[{"id":64716,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64714\/revisions\/64716"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}